[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371594-105":59,"doc-detail-371594-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","snai2-cooperates-with-mek12-and-hdacs-to-suppress-bim-and-bmf-dependent-apoptosis-in-tert-promoter-mutant-cancers","SNAI2 cooperates with MEK1/2 and HDACs to suppress BIM- and BMF-dependent apoptosis in TERT promoter mutant cancers","","Cancers carrying TERT promoter mutations (TPM) show elevated RAS-pathway signaling, mesenchymal traits, and poorer patient survival. The study tested how RAS signaling and mesenchymal features cooperate to resist apoptosis. RAS activity reduced apoptosis by downregulating BIM, and MEK1/2 inhibition restored apoptotic capacity. Combining MEK inhibition with navitoclax increased intrinsic apoptosis, while HDAC inhibitors reprogrammed the mesenchymal state synergistically in a BIM-dependent manner. The apoptosis was DNA-damage independent and depended on SNAI2-mediated regulation and DNA repair.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/snai2-cooperates-with-mek12-and-hdacs-to-suppress-bim-and-bmf-dependent-apoptosis-in-tert-promoter-mutant-cancers/371594/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/snai2-cooperates-with-mek12-and-hdacs-to-suppress-bim-and-bmf-dependent-apoptosis-in-tert-promoter-mutant-cancers/371594.png","ImageObject",300,407,{"name":92,"@type":93},"นรินทร์","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How do TPM cancers become resistant to apoptosis according to the study?","Question",{"text":112,"@type":113},"RAS-pathway signaling in TPM cancers suppresses apoptosis by downregulating the pro-apoptotic protein BIM, reducing intrinsic apoptotic cell death.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the effect of MEK1/2 inhibition on TPM cancer cells?",{"text":117,"@type":113},"Inhibiting MEK1/2 kinases rescues the ability of TPM cancer cells to undergo apoptosis, enabling intrinsic apoptotic processes that depend on BIM.",{"name":119,"@type":110,"acceptedAnswer":120},"How do HDAC inhibitors influence apoptosis in TPM cancers?",{"text":121,"@type":113},"Transcriptional reprogramming of the mesenchymal state using HDAC inhibitors synergistically increases apoptosis, provided BIM is de-repressed; the mechanism is described as independent of DNA damage.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371594,1790878826,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","OPEN ACCESS  \nCitation: Tandon A, Stern JL (2025) SNAI2 cooperates with MEK1/2 and HDACs to suppress BIM-and BMF-dependent apoptosis in TERT promoter mutant cancers. PLoS One 20(6): e0322961. [https://doi.org/10.1371/](https://doi.org/10.1371/)[ ](https://doi.org/10.1371/)[journal.pone.0322961](journal.pone.0322961)  \nEditor: Kai Huang, University of Pennsylvania, UNITED STATES OF AMERICA  \nReceived: October 24, 2024  \nAccepted: March 31, 2025  \nPublished: June 25, 2025  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0322961  \nCopyright: © 2025 Tandon, Stern. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution,  \nRESEARCH ARTICLE  \nSNAI2 cooperates with MEK1/2 and HDACsto suppress BIM-and BMF-dependent apoptosis in TERT promoter mutant cancers  \nAmol Tandon1,2*, Josh Lewis Stern3,4,5  \n1 Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 2 Department of Medical and Translational Biology, Umeå University, Umeå, Sweden, 3 The Center for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 4 Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 5 O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, United States of America  \n* [amol.tandon@umu.se](amol.tandon@umu.se)  \nAbstract  \nCancers with TERT promoter mutations (TPM) display elevated RAS pathway signaling and mesenchymal traits, and associate with lower patient survival rates. We examined whether RAS pathway signaling in TPM cancers cooperates with mesenchymal features to drive resistance to apoptosis. We observed that RAS pathway signaling in TPM cancers inhibited apoptosis by downregulating the pro-apoptotic protein BIM. By using inhibitors of MEK1/2 kinases, we rescued the ability of TPM cancer cells to undergo apoptosis, which may have implications for targeted therapies. To further capitalize on this rescue, we explored combination treatments to drive apoptotic cell death. Treatment with the pan-BCL2 inhibitor, navitoclax (NX), in combination with MEK inhibition, significantly increased apoptosis, indicating that these cells are capable of undergoing intrinsic apoptosis, with BIM likely playing a critical role. Further, we found that transcriptional reprogramming of the mesenchymal state of TPM cancers using histone deacetylase inhibitors (HDACi) resulted in a synergistic increase in apoptosis, contingent upon BIM de-repression. Notably, the cause of this apoptosis appeared to be independent of DNA damage. The suppression of themesenchymal transcription factor SNAI2, which has known roles in recruiting HDACsto silence gene expression, amplified apoptosis. Mechanistically, knockdown of SNAI2 impaired the cellular DNA repair leading to elevated basal levels of phosphorylated H2AX. Our findings show that TPM cancers exhibit specific small molecule vulnerabilities, driven by the convergence of RAS-MEK signaling and impaired HDAC regulation dependent on pro-apoptotic BH3-only proteins. Based on our findings, we propose that stratifying cancers based on TPM may identify a subset of tumors that are responsive to innovative combinations of inhibitors targeting these axes.  \nPLOS One | [https://doi.org/10.1371/journal.pone.0322961](https://doi.org/10.1371/journal.pone.0322961) June 25, 2025 1 / 17  \nand reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All raw data genera","cbCaibmpiDi7BTFW","https://ap.wps.com/l/cbCaibmpiDi7BTFW","pdf",2991581,17,"English","# Abstract\n## RAS-MEK inhibition and apoptosis rescue\n## Combination therapy with navitoclax\n## HDACi reprogramming and synergy\n## Role of SNAI2 and DNA repair\n# Introduction\n## TERT promoter mutations and clinical relevance\n## RAS/EMT linkage to therapy resistance\n## HDAC inhibitors and EMT regulation","[{\"question\":\"How do TPM cancers become resistant to apoptosis according to the study?\",\"answer\":\"RAS-pathway signaling in TPM cancers suppresses apoptosis by downregulating the pro-apoptotic protein BIM, reducing intrinsic apoptotic cell death.\"},{\"question\":\"What is the effect of MEK1/2 inhibition on TPM cancer cells?\",\"answer\":\"Inhibiting MEK1/2 kinases rescues the ability of TPM cancer cells to undergo apoptosis, enabling intrinsic apoptotic processes that depend on BIM.\"},{\"question\":\"How do HDAC inhibitors influence apoptosis in TPM cancers?\",\"answer\":\"Transcriptional reprogramming of the mesenchymal state using HDAC inhibitors synergistically increases apoptosis, provided BIM is de-repressed; the mechanism is described as independent of DNA damage.\"}]","SNAI2 cooperates with MEK1/2 and HDACs to suppress BIM- and BMF-dependent apoptosis in TERT promoter mutant cancers | PDF",1790192409,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3d3b1b7aaeeaf1e95b73e9842593366.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03685de8ba557eafcf346f0d7d76faab.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/704d136656e5d3b0ea68246915d300a7.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50f34964e6a550fcca2b0948de6c5479.webp",980,1268]